Compare Stocks

Comparative Price Performance Over Time

Compare Stocks - Price & Volume

CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Novavax, Inc. stock logo
NVAX
Novavax
$4.71
+0.9%
$4.72
$3.53
$11.36
$661.28M1.637.25 million shs3.66 million shs
Pfizer Inc. stock logo
PFE
Pfizer
$27.70
+1.9%
$26.88
$25.20
$40.37
$156.85B0.6342.88 million shs63.86 million shs
The Best High-Yield Dividend Stocks for 2024 Cover

Looking to generate income with your stock portfolio? Use these ten stocks to generate a safe and reliable source of investment income.

Get This Free Report

Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Novavax, Inc. stock logo
NVAX
Novavax
+7.85%+12.53%+0.43%+16.17%-33.66%
Pfizer Inc. stock logo
PFE
Pfizer
+6.09%+3.47%-1.91%-0.40%-30.44%

MarketRank™

CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & Valuation
Novavax, Inc. stock logo
NVAX
Novavax
3.7388 of 5 stars
3.52.00.04.71.70.80.6
Pfizer Inc. stock logo
PFE
Pfizer
4.9984 of 5 stars
4.23.04.24.83.11.73.1

Analyst Ratings

CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
Novavax, Inc. stock logo
NVAX
Novavax
3.00
Buy$17.00260.93% Upside
Pfizer Inc. stock logo
PFE
Pfizer
2.38
Hold$36.0029.96% Upside

Current Analyst Ratings

Latest NVAX and PFE Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
5/2/2024
Pfizer Inc. stock logo
PFE
Pfizer
Morgan Stanley
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost Price TargetEqual Weight ➝ Equal Weight$28.00 ➝ $29.00
5/2/2024
Pfizer Inc. stock logo
PFE
Pfizer
BMO Capital Markets
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingOutperform ➝ Outperform$33.00 ➝ $36.00
4/15/2024
Pfizer Inc. stock logo
PFE
Pfizer
Cantor Fitzgerald
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingOverweight ➝ Overweight$45.00
4/1/2024
Pfizer Inc. stock logo
PFE
Pfizer
Cantor Fitzgerald
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingOverweight ➝ Overweight$45.00
3/22/2024
Pfizer Inc. stock logo
PFE
Pfizer
Argus
Subscribe to MarketBeat All Access for the recommendation accuracy rating
DowngradeBuy ➝ Hold
3/1/2024
Novavax, Inc. stock logo
NVAX
Novavax
HC Wainwright
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetBuy ➝ Buy$35.00 ➝ $19.00
3/1/2024
Pfizer Inc. stock logo
PFE
Pfizer
Cantor Fitzgerald
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingOverweight ➝ Overweight$45.00
2/23/2024
Pfizer Inc. stock logo
PFE
Pfizer
Guggenheim
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Initiated CoverageBuy$36.00
(Data available from 5/2/2021 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Sales & Book Value

CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
Novavax, Inc. stock logo
NVAX
Novavax
$983.71M0.67N/AN/A($6.04) per share-0.78
Pfizer Inc. stock logo
PFE
Pfizer
$58.50B2.68$3.22 per share8.61$15.81 per share1.75

Profitability & Earnings

CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
Novavax, Inc. stock logo
NVAX
Novavax
-$545.06M-$5.53N/AN/AN/A-55.41%N/A-32.63%5/14/2024 (Estimated)
Pfizer Inc. stock logo
PFE
Pfizer
$2.12B$0.3676.9410.111.153.62%10.88%4.91%8/6/2024 (Estimated)

Latest NVAX and PFE Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
5/1/2024Q1 2024
Pfizer Inc. stock logo
PFE
Pfizer
$0.56$0.82+$0.26$1.09$13.87 billion$14.88 billion    
2/28/2024Q4 2023
Novavax, Inc. stock logo
NVAX
Novavax
-$0.49-$1.44-$0.95-$1.44$310.96 million$291.34 million      

Dividends

CompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive Growth
Novavax, Inc. stock logo
NVAX
Novavax
N/AN/AN/AN/AN/A
Pfizer Inc. stock logo
PFE
Pfizer
$1.686.06%+2.57%466.67%15 Years

Latest NVAX and PFE Dividends

AnnouncementCompanyPeriodAmountYieldEx-Dividend DateRecord DatePayable Date
4/24/2024
Pfizer Inc. stock logo
PFE
Pfizer
quarterly$0.426.4%5/9/20245/10/20246/14/2024
(Data available from 1/1/2013 forward)

Debt

CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
Novavax, Inc. stock logo
NVAX
Novavax
N/A
0.70
0.67
Pfizer Inc. stock logo
PFE
Pfizer
0.69
0.91
0.69

Ownership

Institutional Ownership

CompanyInstitutional Ownership
Novavax, Inc. stock logo
NVAX
Novavax
53.04%
Pfizer Inc. stock logo
PFE
Pfizer
68.36%

Insider Ownership

CompanyInsider Ownership
Novavax, Inc. stock logo
NVAX
Novavax
0.90%
Pfizer Inc. stock logo
PFE
Pfizer
0.06%

Miscellaneous

CompanyEmployeesShares OutstandingFree FloatOptionable
Novavax, Inc. stock logo
NVAX
Novavax
1,543140.40 million138.69 millionOptionable
Pfizer Inc. stock logo
PFE
Pfizer
88,0005.66 billion5.66 billionOptionable

NVAX and PFE Headlines

SourceHeadline
Principle Wealth Partners LLC Has $5.63 Million Stake in Pfizer Inc. (NYSE:PFE)Principle Wealth Partners LLC Has $5.63 Million Stake in Pfizer Inc. (NYSE:PFE)
marketbeat.com - May 2 at 10:45 PM
Pfizer Q1 earnings: non-Covid product sales help post revenues of $14.9 billion despite Comirnaty, Paxlovid declinePfizer Q1 earnings: non-Covid product sales help post revenues of $14.9 billion despite Comirnaty, Paxlovid decline
msn.com - May 2 at 9:58 PM
Pfizer Prospects Garner Mixed Sentiment From Analysts: Finally, The Pivot Investors Have Been Waiting ForPfizer Prospects Garner Mixed Sentiment From Analysts: 'Finally, The Pivot Investors Have Been Waiting For'
markets.businessinsider.com - May 2 at 9:58 PM
Pfizer (NYSE:PFE) Announces Quarterly  Earnings ResultsPfizer (NYSE:PFE) Announces Quarterly Earnings Results
marketbeat.com - May 2 at 4:04 PM
Pfizer (NYSE:PFE) Trading Up 1.8% After Better-Than-Expected EarningsPfizer (NYSE:PFE) Trading Up 1.8% After Better-Than-Expected Earnings
marketbeat.com - May 2 at 2:47 PM
Pfizer (NYSE:PFE) Price Target Raised to $29.00Pfizer (NYSE:PFE) Price Target Raised to $29.00
marketbeat.com - May 2 at 1:32 PM
Pfizer Inc. (NYSE:PFE) Q1 2024 Earnings Call TranscriptPfizer Inc. (NYSE:PFE) Q1 2024 Earnings Call Transcript
finance.yahoo.com - May 2 at 1:30 PM
BMO Capital Markets Reiterates "Outperform" Rating for Pfizer (NYSE:PFE)BMO Capital Markets Reiterates "Outperform" Rating for Pfizer (NYSE:PFE)
marketbeat.com - May 2 at 11:13 AM
Pfizer Stock: Finally The Market Is Waking UpPfizer Stock: Finally The Market Is Waking Up
seekingalpha.com - May 2 at 8:29 AM
3 Contrarian Stocks That Could Make You a Fortune (If You Dare)3 Contrarian Stocks That Could Make You a Fortune (If You Dare)
investorplace.com - May 2 at 7:22 AM
My Top 5 Favorite High-Yield Dividend Stocks to Buy in MayMy Top 5 Favorite High-Yield Dividend Stocks to Buy in May
fool.com - May 2 at 5:50 AM
Pfizers Stock Is a Buy. Here Are Six Reasons Why.Pfizer's Stock Is a Buy. Here Are Six Reasons Why.
fool.com - May 2 at 5:15 AM
Q1 2024 Pfizer Inc Earnings Call TranscriptQ1 2024 Pfizer Inc Earnings Call Transcript
gurufocus.com - May 2 at 1:01 AM
Raymond James Financial Services Advisors Inc. Grows Stake in Pfizer Inc. (NYSE:PFE)Raymond James Financial Services Advisors Inc. Grows Stake in Pfizer Inc. (NYSE:PFE)
marketbeat.com - May 1 at 11:16 PM
Pfizer stock gains 7% after earnings beat, company calls dividend securePfizer stock gains 7% after earnings beat, company calls dividend 'secure'
msn.com - May 1 at 8:39 PM
Pfizer (PFE) Q1 2024 Earnings Call TranscriptPfizer (PFE) Q1 2024 Earnings Call Transcript
fool.com - May 1 at 8:39 PM
Why Pfizer Stock Blasted More Than 6% Higher TodayWhy Pfizer Stock Blasted More Than 6% Higher Today
fool.com - May 1 at 5:55 PM
PFE Earnings: Pfizer Rises After Smashing Q1 EstimatesPFE Earnings: Pfizer Rises After Smashing Q1 Estimates
msn.com - May 1 at 3:39 PM
Pfizer (NYSE:PFE) Stock Price Up 3.8%Pfizer (NYSE:PFE) Stock Price Up 3.8%
marketbeat.com - May 1 at 1:59 PM
Pfizer Stock Gets Boost From Better-Than-Expected EarningsPfizer Stock Gets Boost From Better-Than-Expected Earnings
investopedia.com - May 1 at 1:46 PM
Pfizer (PFE) Q1 Earnings & Sales Top, EPS Guidance RaisedPfizer (PFE) Q1 Earnings & Sales Top, EPS Guidance Raised
zacks.com - May 1 at 12:46 PM
Pfizer raises guidance amid cost savingsPfizer raises guidance amid cost savings
msn.com - May 1 at 10:38 AM
Pfizer Stock Rises as Outlook Rises After Earnings BeatPfizer Stock Rises as Outlook Rises After Earnings Beat
finance.yahoo.com - May 1 at 10:38 AM
Pfizer Inc (PFE) Q1 2024 Earnings: Adjusted EPS Surpasses Expectations Amidst Revenue DeclinePfizer Inc (PFE) Q1 2024 Earnings: Adjusted EPS Surpasses Expectations Amidst Revenue Decline
finance.yahoo.com - May 1 at 10:38 AM

New MarketBeat Followers Over Time

Media Sentiment Over Time

Company Descriptions

Novavax logo

Novavax

NASDAQ:NVAX
Novavax, Inc., a biotechnology company, that promotes improved health by discovering, developing, and commercializing vaccines to protect against serious infectious diseases. It offers vaccine platform that combines a recombinant protein approach, nanoparticle technology, and its patented Matrix-M adjuvant to enhance the immune response. It focuses on urgent health challenges, which is evaluating vaccines for COVID-19, influenza, and COVID-19 influenza combination. The company is commercializing a COVID-19 vaccine, NVX-CoV2373 under the brand names of Nuvaxovid, Covovax, and Novavax COVID-19 Vaccine, adjuvanted for adult and adolescent populations as a primary series and for both homologous and heterologous booster indications. It is also developing R21/Matrix-M adjuvant malaria vaccine. Novavax, Inc. was incorporated in 1987 and is headquartered in Gaithersburg, Maryland.
Pfizer logo

Pfizer

NYSE:PFE
Pfizer Inc. discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands. It also provides medicines and vaccines in various therapeutic areas, such as biosimilars for chronic immune and inflammatory diseases under the Xeljanz, Enbrel, Inflectra, Litfulo, Velsipity, and Cibinqo brands; amyloidosis, hemophilia, endocrine diseases, and sickle cell disease under the Vyndaqel family, Oxbryta, BeneFIX, Somavert, Ngenla, and Genotropin brands; sterile injectable and anti-infective medicines under the Sulperazon, Medrol, Zavicefta, Zithromax, and Panzyga brands; and biologics, small molecules, immunotherapies, and biosimilars under the Ibrance, Xtandi, Inlyta, Bosulif, Mektovi, Padcev, Adcetris, Talzenna, Tukysa, Elrexfio, Tivdak, Lorbrena, and Braftovi brands. In addition, the company involved in the contract manufacturing business. It serves wholesalers, retailers, hospitals, clinics, government agencies, pharmacies, individual provider offices, retail pharmacies, and integrated delivery systems. The company has collaboration agreements with Bristol-Myers Squibb Company; Astellas Pharma US, Inc.; Merck KGaA; and BioNTech SE. Pfizer Inc. was founded in 1849 and is headquartered in New York, New York.